Cargando…
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
TP53 is a key tumor suppressor gene that plays an important role in regulating apoptosis, senescence, and DNA damage repair in response to cellular stress. Although somewhat rare, TP53-mutated AML has been identified as an important molecular subgroup with a prognosis that is arguably the worst of a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037178/ https://www.ncbi.nlm.nih.gov/pubmed/35479302 http://dx.doi.org/10.2147/OTT.S265637 |
_version_ | 1784693678105690112 |
---|---|
author | Granowicz, Eric M Jonas, Brian A |
author_facet | Granowicz, Eric M Jonas, Brian A |
author_sort | Granowicz, Eric M |
collection | PubMed |
description | TP53 is a key tumor suppressor gene that plays an important role in regulating apoptosis, senescence, and DNA damage repair in response to cellular stress. Although somewhat rare, TP53-mutated AML has been identified as an important molecular subgroup with a prognosis that is arguably the worst of any. Survival beyond one year is rare after induction chemotherapy with or without consolidative allogeneic stem cell transplant. Although response rates have been improved with hypomethylating agents, outcomes remain particularly poor due to short response duration. Improvements in our understanding of AML genetics and biology have led to a surge in novel treatment options, though the clinical applicability of these agents in TP53-mutated disease remains largely unknown. This review will focus on the epidemiology, molecular characteristics, and clinical significance of TP53 mutations in AML as well as emerging treatment options that are currently being studied. |
format | Online Article Text |
id | pubmed-9037178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90371782022-04-26 Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments Granowicz, Eric M Jonas, Brian A Onco Targets Ther Review TP53 is a key tumor suppressor gene that plays an important role in regulating apoptosis, senescence, and DNA damage repair in response to cellular stress. Although somewhat rare, TP53-mutated AML has been identified as an important molecular subgroup with a prognosis that is arguably the worst of any. Survival beyond one year is rare after induction chemotherapy with or without consolidative allogeneic stem cell transplant. Although response rates have been improved with hypomethylating agents, outcomes remain particularly poor due to short response duration. Improvements in our understanding of AML genetics and biology have led to a surge in novel treatment options, though the clinical applicability of these agents in TP53-mutated disease remains largely unknown. This review will focus on the epidemiology, molecular characteristics, and clinical significance of TP53 mutations in AML as well as emerging treatment options that are currently being studied. Dove 2022-04-21 /pmc/articles/PMC9037178/ /pubmed/35479302 http://dx.doi.org/10.2147/OTT.S265637 Text en © 2022 Granowicz and Jonas. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Granowicz, Eric M Jonas, Brian A Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title | Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title_full | Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title_fullStr | Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title_full_unstemmed | Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title_short | Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments |
title_sort | targeting tp53-mutated acute myeloid leukemia: research and clinical developments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037178/ https://www.ncbi.nlm.nih.gov/pubmed/35479302 http://dx.doi.org/10.2147/OTT.S265637 |
work_keys_str_mv | AT granowiczericm targetingtp53mutatedacutemyeloidleukemiaresearchandclinicaldevelopments AT jonasbriana targetingtp53mutatedacutemyeloidleukemiaresearchandclinicaldevelopments |